Motoko Yamaguchi

10PUBLICATIONS
10CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumoursPredictive and prognostic markersOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 25, 2026
Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

|Apr 09, 2026
Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.

Kazutaka Suzuki, Kana Miyazaki, Naoko Asano

|Dec 16, 2025
Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER).

Yusuke Sano, Kana Miyazaki, Motoko Yamaguchi

|Feb 12, 2025
Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.

Yuma Nato, Kana Miyazaki, Dai Maruyama

|Feb 10, 2022
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.

Kana Miyazaki, Ritsuro Suzuki, Masahiko Oguchi

|Jan 30, 2020
Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.

Akihiko Sawaki, Kana Miyazaki, Motoko Yamaguchi

Pageof 2

Frequent Collaborators

5 joint publications

Kana Miyazaki

2 joint publications

Senzo Taguchi

2 joint publications

Dai Maruyama

2 joint publications

Ilseung Choi